Inovio: European COMP provides positive opinion on INO-3107

Inovio announced that the European Committee for Orphan Medicinal Products has provided a positive opinion on Inovio’s application for orphan drug designation in the European Union for INO-3107. INO-3107 is the company’s product candidate that may contribute to the treatment of Recurrent Respiratory Papillomatosis. The opinion is now with the European Commission, which will provide a final decision on the application within 30 days.